Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy.
aptamer
gold nanocage
immune checkpoint blockade
light targeting
photothermal therapy
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
28 Sep 2022
28 Sep 2022
Historique:
pubmed:
14
9
2022
medline:
1
10
2022
entrez:
13
9
2022
Statut:
ppublish
Résumé
Immune checkpoint blockade (ICB) has been hailed as the hope for conquering cancer as ICB could produce a significant and durable response to tumor cells. However, the high cost and severe side effects of ICB drugs limited their application for further anticancer therapy. Here, we developed a photoactivated immunotherapy nanoplatform (Apt@AuNC). This nanoplatform could target tumor tissues via enhanced penetration retention (EPR) effect and the aptamer (Apt) could be released from Apt@AuNC in tumor sites via illumination. The immune system in the tumor area was then activated after the combination of Apt and PD-1 protein. The heat generated from AuNC was able to continue killing tumor cells. This nanoplatform could not only achieve the precise immunotherapy but also significantly facilitate the anticancer efficacy.
Identifiants
pubmed: 36099584
doi: 10.1021/acsami.2c11089
doi:
Substances chimiques
Aptamers, Nucleotide
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
APT
7320-57-2
Gold
7440-57-5
Dimaprit
ZZQ699148P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM